MAIA

MAIA Biotechnology, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

MAIAMaia Biotechnology
0Calm
THIO Sequenced With Cemiplimab in Advanced NSCLC
Running, no new patientsPhase 2227 patientsMain results: Sep 30, 2027
MAIAMaia Biotechnology
0Calm
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Signing up patientsPhase 3300 patientsMain results: Jul 31, 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 10 purchases

Vitoc VladChief Executive Officer · Sep 14, 2026Bought 73,000 sharesabout $100 thousand ·
Guerrero RamiroBoard member · Sep 10, 2026Bought 37,595 sharesabout $50 thousand ·
Guerrero RamiroBoard member · Aug 28, 2026Bought 46,620 sharesabout $63 thousand ·
Guerrero RamiroBoard member · Aug 27, 2026Bought 78,239 sharesabout $109 thousand ·
Guerrero RamiroBoard member · Aug 26, 2026Bought 8,931 sharesabout $12 thousand ·
Guerrero RamiroBoard member · Aug 24, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.